期刊文献+

利拉鲁肽对动脉硬化大鼠模型的疗效评价 被引量:1

Efficacy of liraglutide on atherosclerotic rat model
下载PDF
导出
摘要 目的根据血管张力、血管病理及血清学指标来评价利拉鲁肽治疗高脂诱导动脉硬化大鼠模型的疗效。方法32只SPF级雄性大鼠,随机分为高脂组20只、对照组12只。将造模成功的高脂组随机分为利拉鲁肽组和安慰剂组,并继续给予高脂饲料喂养,同时分别皮下注射利拉鲁肽或生理盐水,对照组继续给予普通饲料喂养。干预16周末,检测血清三酰甘油(TG)、总胆固醇(CHO)、低密度脂蛋白(LDL)、空腹血糖(FBG)、空腹胰岛素(FINS)水平,检测血清一氧化氮(NO)和内皮素1(ET-1)水平评价血管内皮功能改变;血管组织HE染色及Masson染色观察血管壁改变;血管张力检测仪检测各组大鼠血管张力变化。采用方差齐性检验分析实验数据。结果与安慰剂组相比,利拉鲁肽组大鼠血清TG、CHO、LDL、FINS、ET-1水平均明显下降(P<0.05),NO水平升高(P<0.05);血管病理结果显示血管内皮损伤程度显著减轻,血管平滑肌细胞增殖及迁移减少;血管张力检测结果显示利拉鲁肽组血管舒张功能显著改善(P<0.05)。结论利拉鲁肽能明显减轻高脂饮食诱导的动脉硬化大鼠的血管内皮损伤,保护内皮细胞,抑制平滑肌细胞增殖及迁移,有可能成为改善动脉硬化程度的新药物。 Objective The curative effect of liraglutide on rat model of atherosclerosis induced by high fat was evaluated according to vascular tone,vascular pathology and serological indexes. Methods Thirty SDF male rats were randomly divided into high fat group( n = 20) and control group( n = 12). The successful model of high fat group were randomly divided into liraglutide group and placebo group,and continue to be given high-fat diet,respectively,while subcutaneous injection of liraglutide or saline,the control group continue to be fed ordinary feed.At the end of the 16 th week of intervention,serum triglyceride( TG),total cholesterol( CHO),low density lipoprotein( LDL),fasting blood glucose( FBG) and fasting insulin( FINS) were measured; the changes of vascular endothelial function were evaluated by the level of serum nitric oxide( NO) and endothelin 1( ET-1); the vascular wall was observed by HE staining and Masson staining; the vascular tension was detected by aorta-ring apparatus.The data were analyzed by means of homogeneity of variance. Results Compared with placebo group,the levels of serum TG,CHO,LDL,FINS and ET-1 in liraglutide group were significantly decreased( P 〈 0. 05) and NO levels were increased( P 〈 0. 05); the results of vascular pathology showed that the degree of vascular endothelial injury was significantly reduced and the proliferation and migration of vascular smooth muscle cells were decreased; the results of aorta-ring results showed that the vasodilation of liraglutide group was significantly improved( P 〈 0. 05).Conclusion liraglutide can significantly reduce the vascular endothelial injury induced by high-fat diet,protect endothelial cells and inhibit the proliferation and migration of smooth muscle cells,which may become a new drug to improve the degree of atherosclerosis.
作者 郭晶晶 李娜 霍琴琴 钟兴 潘天荣 Guo Jingjing;Li Na;Huo Qinqin(Dept of Endocrinology,The Second Affiliated Hospital of Anhui Medical University,Hefei 230601;The Affiliated Fuyang Hospital of Anhui Medical University,Fuyang 236000)
出处 《安徽医科大学学报》 CAS 北大核心 2018年第6期902-907,共6页 Acta Universitatis Medicinalis Anhui
基金 安徽省科技厅公益性技术应用研究联动项目(编号:1501ld04042) 安徽省高等学校自然科学研究重点项目(编号:KJ2017A174 KJ2018A0202)
关键词 利拉鲁肽 动脉硬化 血管张力 内皮素1 一氧化氮 liraglutide atherosclerosis vascular tension endothelin 1 nitric oxide
  • 相关文献

参考文献1

二级参考文献19

  • 1Nystrom T, Gumiak MK, Zhang O, et al. Effects of glucagon-like peptide-I on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Phsial Endocrinol Metab, 2004, 287: E1209-E1215.
  • 2Frezza EE, Wachtel MS, Chiriva-Internati M. The Multiple Faces of Glucagon-Like Peptide-l--Obesity, Appetite, and Stress: What Is Next? A Review. Dig Dis Sci, 2007, 52: 643-649.
  • 3Lorber D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther, 2013, 31: 238-249.
  • 4Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide-1 can directly protect the heart against isehemia/reperfusion injury. Diabetes, 2005, 54: 146-151.
  • 5Michael AN. Liraglutide, a once-daily human GLP-1 analogue. Br J Diabetes Vasc Dis, 2008, 8 (Suppl 2): S26-S33.
  • 6Gaspari T, Welungoda I, Widdnp RE. The GLP-I receptor agonist liraglulide inhibits progression of vascuklar disease ,eia effects on atheragenesis, plaque stability and endothelial function in an ApoE (-/-) mouse model. Diab Vasc Dis Res, 2013, 10: 353-360.
  • 7Abu-Hamdah R, Rabiee A, Meneilly GS, et al. Clinical review: The extrapancreatic effects of glucagon-like eptide-1 and related peptides. J Clin Endncrinol Metab. 2009.94: 1843-1852.
  • 8Golpon HA, Puechner A, Welte T, et al. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept, 2001, 102: 81-86.
  • 9Segal SS, Jacobs TL, Role for endothelial cell conduction in ascending vasodilatation and exercise hyperaemia in hamster skeletal muscle. J Physiol, 2001, 536: 937-9d-6.
  • 10Saraceni C, Broderick TL. Effects of g|ucagnn-like peptide-I and long-aeting analogues on cardiovascular and metabolic function. Drugs R D, 2007, 8: 145-153.

共引文献7

同被引文献14

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部